Home  |  Contact

Cellosaurus MCF-7/164R-5 (CVCL_1D38)

[Text version]

Cell line name MCF-7/164R-5
Synonyms MCF7/164R-5; MCF-7/164(R)-5; 164R-5
Accession CVCL_1D38
Resource Identification Initiative To cite this cell line use: MCF-7/164R-5 (RRID:CVCL_1D38)
Comments Population: Caucasian.
Selected for resistance to: ChEBI; CHEBI:31638; Fulvestrant (ICI 182780).
Sequence variations Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line).
Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line).
Disease Invasive breast carcinoma of no special type (NCIt: C4194)
Derived from metastatic site: Pleural effusion.
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_1D47 (MCF-7/S0.5)
Sex of cell Female
Age at sampling 69Y
Category Cancer cell line
Publications

PubMed=7759159; DOI=10.1002/ijc.2910610417
Lykkesfeldt A.E., Larsen S.S., Briand P.
Human breast cancer cell lines resistant to pure anti-estrogens are sensitive to tamoxifen treatment.
Int. J. Cancer 61:529-534(1995)

PubMed=16172194; DOI=10.1677/erc.1.00946
Frogne T., Jepsen J.S., Larsen S.S., Fog C.K., Brockdorff B.L., Lykkesfeldt A.E.
Antiestrogen-resistant human breast cancer cells require activated protein kinase B/Akt for growth.
Endocr. Relat. Cancer 12:599-614(2005)

PubMed=25362855; DOI=10.1038/onc.2014.351
Thrane S., Pedersen A.M., Thomsen M.B.H., Kirkegaard T., Rasmussen B.B., Duun-Henriksen A.K., Laenkholm A.-V., Bak M., Lykkesfeldt A.E., Yde C.W.
A kinase inhibitor screen identifies Mcl-1 and Aurora kinase A as novel treatment targets in antiestrogen-resistant breast cancer cells.
Oncogene 34:4199-4210(2015)

Cross-references
Cell line collections Ximbio; 152102
Other Wikidata; Q54904340
Entry history
Entry creation08-Jul-2015
Last entry update20-May-2021
Version number12